UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                                   FORM 10-K

                ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
                      THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended     December 31, 2010
                              --------------------------------------------------

Commission file number        000-15303
                              --------------------------------------------------

                                HST Global, Inc.
--------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                 NEVADA                         73-1215433
--------------------------------------------------------------------------------
      (STATE OR OTHER JURISDICTION     (IRS EMPLOYER IDENTIFICATION NO.)
            OF INCORPORATION)

                     150 Research Drive, Hampton, VA 23666
--------------------------------------------------------------------------------
          (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)  (ZIP CODE)

Registrant's telephone number, including area code:  757-766-6100
                                                     ---------------------------

                                    Copy to:

                                Cutler Law Group
                         3355 W. Alabama St. Ste. 1150
                               Houston, TX 77098
                               Fax: 800-836-0714

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class                    Name of Each Exchange on which Registered

None                                   None
--------------------------------------------------------------------------------

          Securities registered pursuant to Section 12(g) of the Act:

                        Common Stock ($0.001 par value)
--------------------------------------------------------------------------------
                                (Title of Class)

<PAGE>
Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.                      [ ] Yes   [x] No

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act.             [ ] Yes   [x] No

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.                              [x] Yes   [ ] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K (  229.405 of this chapter) is not contained herein, and will
not be contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K.                                          [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
definition of "accelerated filer, large accelerated filer and smaller reporting
company" as defined in Rule 12b-2 of the Exchange Act.

Large accelerated filer     [ ]               Accelerated filer              [ ]
Non-accelerated filer       [ ]               Smaller reporting company      [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act).                                         [ ] Yes   [x] No

The aggregate market value of the common equity held by non-affiliates of the
registrant as of June 30, 2010 was  $24,998,387.

The number of shares of the registrant's common stock outstanding as of May 13,
2011 was 28,719,854 shares.















                                     Page 2
<PAGE>
                                HST GLOBAL, INC.
                               TABLE OF CONTENTS

                                     PART I

Forward Looking Statements                                                     4
Item 1.   Business                                                             4
Item 1A.  Risk Factors                                                         6
Item 1B.  Unresolved Staff Comments                                            6
Item 2.   Properties                                                           6
Item 3.   Legal Proceedings                                                    7
Item 4.   [Removed and Reserved]                                               7

                                    PART II

Item 5.   Market for Registrant's Common Equity, Related Stockholder
          Matters and Issuer Purchases of Equity Securities                    7
Item 6.   Selected Financial Data                                             10
Item 7.   Management's Discussion and Analysis of Financial Condition
          and Results of Operations                                           10
Item 7A.  Quantitative and Qualitative Disclosures About Market Risk          11
Item 8.   Financial Statements and Supplementary Data                         11
Item 9.   Changes in and Disagreements with Accountants on
          Accounting and Financial Disclosure                                 25
Item 9A.  Controls and Procedures                                             25
Item 9B.  Other Information                                                   26


                                    PART III

Item 10.  Directors and Executive Officers of the Registrant                  26
Item 11.  Executive Compensation                                              28
Item 12.  Security Ownership of Certain Beneficial Owners and Management      32
Item 13.  Certain Relationships and Related Transactions                      32
Item 14.  Principal Accounting Fees and Services                              33


PART IV

Item 15.  Exhibits and Financial Statement Schedules                          33
Signatures                                                                    34









                                     Page 3
<PAGE>
FORWARD-LOOKING  STATEMENTS

In addition to historical information, this Report contains forward-looking
statements. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
reflected in these forward-looking statements. Factors that might cause such a
difference include, but are not limited to, management of growth, competition,
pricing pressures on the Company's products, industry growth and general
economic conditions. Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect management's opinions only as of the
date hereof. The Company undertakes no obligation to revise or publicly release
the results of any revision to these forward-looking statements.

                                     PART I
ITEM 1. BUSINESS

A. BUSINESS DEVELOPMENT

The continual evolution in the discovery of new "cutting edge" ingredients and
the development in understanding the manner in which they can impact overall
heath serve as a reminder to emerging technologies and gateways for treating an
individual's challenges with regard to their personal health.  The executive
team of HST continues to enjoy an unusual position of visibility with
organizations involved in developing many of these new products and
technologies.  Consequently, the year ending December 31, 2010 has positioned
the company to investigate some of these emerging technologies for acquisition
and/or potential Joint Venture Agreements.

A confluence of opportunity, some old, some new, is pushing us to consider using
these new technologies and developing new channels of distribution both within
the structure of our original clinics and additionally through physician
networks.

B. FINANCIAL INFORMATION ABOUT SEGMENTS

As defined by generally accepted accounting principles ("GAAP"), we do not have
any segments separate and apart from our business as a whole. Accordingly, there
are no measures of revenue from external customers, profit and loss, or total
assets aside from what is reported in the Financial Statements attached to this
Form 10-K.

C. BUSINESS OF THE COMPANY

COMPANY OVERVIEW

HST Global, Inc. is an Integrated Health and Wellness company that is developing
and/or acquiring a network of Wellness Centers worldwide that are primarily
focused on the homeopathic and alternative treatment of late stage cancer. In
addition, the company intends to acquire innovative products for the treatment
of late stage cancer. In this regard, the company primarily focuses on
homeopathic and alternative product candidates that are undergoing or have
already completed significant clinical testing for the treatment of late stage
cancer.  The development of new and emerging technologies will broaden the
company's direction and incorporate products that are associated with the
biotechnology industry.  They will strengthen the company's relationship with
its targeted clinical partners and broaden the channels of distribution
currently available to the company.

The company has identified the growing acceptance of alternative cancer
treatments worldwide which has placed us in a perfect position to open our own
brand of Cancer Treatment Centers. This strategy will

                                     Page 4
<PAGE>
enable the company to address the challenges individuals face in the treatment
of cancer in the later stages.

The Company has been challenged in the execution of its intention to open Cancer
Centers that were originally targeted to be opened this year.  Our inability to
raise sufficient money coupled with the down turn in the economy of 2010 has
delayed opening new locations.

 Our executive offices are located at 150 Research Drive Hampton, VA 23666. Our
telephone number is 757-766-6100 and our internet address is www.hstglobal.com.

BUSINESS MODEL AND STRATEGY

Cancer is an epidemic that is worldwide and one that does not discriminate. The
company has been involved with pre-clinical and proven product candidates that
have shown high efficacy in the treatment of various late stage cancers. The
success and high efficacy achieved in these treatments has given the company a
position of visibility that has attracted a number of International partners
that want to move forward and open Centers worldwide. Movement to establish a
global chain of Cancer Treatment Centers will provide an immediate revenue
stream to the company.

Due to the change in the perception of homeopathic treatments for cancer and
other life threatening illnesses, the company has developed a strategy of
opening a chain of Wellness Centers worldwide.  It is the company's intention to
open its first clinic during the fourth quarter of 2011.  After an initial one
year ramp-up period, anticipated annual gross revenues for each individual
clinic should be approximately between 8 and 10 million dollars per year.

As referenced above, the company also focuses on alternative and homeopathic
products that are undergoing or have already completed significant clinical
testing for the treatment of late stage cancer. Currently, we do not follow any
policy or formula as to our acquisition of product candidates, other than
seeking products for which pre-clinical or clinical testing has commenced.

REPORT BY THE SCIENTIFIC ADVISORY BOARD

The following summarizes the findings of our Scientific Advisory Board with
respect to the ongoing clinical trials:

The purpose of the pre-clinical outcome-based study in Stage IV adult cancers is
to study efficacy and safety issues. All patients coming to the clinic are given
the following choices:

1.     Conventional chemotherapy, either first, second or third line, as
       appropriate to the patient's prior history;
2.     Conventional chemotherapy, either standard or low-dose fractionated, with
       proprietary immune therapies;
3.     Conventional dose or low-dose fractionated chemotherapy with other
       complimentary products;
4.     Insulin Potentiated Therapy using standard chemotherapy with other
       complimentary therapies, and
5.     Any of the above plus hormonal therapies.

The advantages of the pre-clinical studies are to show efficacy and safety, and
freedom from adverse toxicities and adverse side-effects. The ongoing conclusion
of the studies are that there is a novel, homeopathic, immune boosting therapy
that when used alone in cancer, is showing an overall high response rate.

                                     Page 5
<PAGE>
OTHER MATTERS

EMPLOYEES
---------

HST Global, Inc. and Health Source Technologies, Inc., our wholly owned
subsidiary, have a total of one full and one part time employees and one
consultant who devote a significant portion of their time to the Company. We
believe our relationship with our employees is good.

RESEARCH AND DEVELOPMENT
------------------------

During the last two full fiscal years, we have not engaged in any research and
development activities. Our business model is to in-license technologies
developed by others. In the event that we undertake research and development
activities in the future, the costs of those efforts will not be bourn directly
by our consumers.

INTELLECTUAL PROPERTY
---------------------

Our goal is to obtain, maintain and enforce patent protection for our products,
formulations, processes, methods and other proprietary technologies, preserve
our trade secrets, and operate without infringing on the proprietary rights of
other parties, both in the United States and in other countries. Our policy is
to actively seek to obtain, where appropriate, the broadest intellectual
property protection possible for any future product candidates, proprietary
information and proprietary technology through a combination of contractual
arrangements and patents, both in the U.S. and abroad.

DEPENDENCE ON ONE OR A FEW MAJOR CUSTOMERS
------------------------------------------

HSTC is not dependent on one or a few major customers.

COMPETITION
-----------

The treatment of late stage cancer is highly competitive, and there will be
considerable competition from major pharmaceutical, biotechnology, and specialty
cancer companies. Many of our competitors have substantially more resources than
we do, including both financial and technical resources. In addition, many of
these companies have more experience than we do in preclinical and clinical
development, manufacturing, regulatory, and global commercialization. We are
also competing with academic institutions, governmental agencies and private
organizations that are conducting research in the field of cancer. Competition
for highly qualified employees is intense.

ITEM 1A. RISK FACTORS

Not required by smaller reporting companies.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

The Company's executive offices are located at 150 Research Dr., Hampton VA. We
currently share these offices with The Health Network, Inc. ("THN"), of which
Ron Howell is President. We have no formal

                                     Page 6
<PAGE>
sublease or rental agreement with THN; however, we currently pay to THN $15,000
per month as an operating fee, which includes use of the office space among
other things. The combined office and warehouse space is 42,600 square feet.

ITEM 3. LEGAL PROCEEDINGS

The Company had entered to certain loan agreements as referenced in Note 7 of
the Financial Statements for the Year Ended December 31, 2010.  Facts have come
to the Company's attention that causes the Company to believe that the debts
have been extinguished.  However, the Company cannot offer any assurance that
the holders of the debt will not seek to enforce rights that the holders believe
they may have under the respective agreements.

ITEM 4. [REMOVED AND RESERVED]


                                    PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES

MARKET INFORMATION

Our common stock is quoted in United States markets on the Over-The-Counter
Bulletin Boards ("OTC BB"), under the symbol "HSTC.OB." There is no assurance
that the common stock will continue to be traded on the OTC BB or that any
liquidity exists for our shareholders.

MARKET PRICE

The following table shows the high and low per share price quotations of the
Company's common stock as reported by the OTC BB for the periods presented.
These quotations reflect inter-dealer prices, without retail mark-up, mark-down
or commissions, and may not necessarily represent actual transactions. The OTC
BB market is extremely limited and the prices quoted by brokers are not a
reliable indication of the value of the common stock. The periods presented
represent fiscal quarters, with the fourth quarter of each year ending on
December 31.

                                      High  Low
     Fiscal 2009
        First Quarter                 3.13  0.80
        Second Quarter                2.25  0.80
        Third Quarter                 1.12  0.15
        Fourth Quarter                0.33  0.07

     Fiscal 2010
        First Quarter                 0.46  0.19
        Second Quarter                0.55  0.20
        Third Quarter                 0.27  0.14
        Fourth Quarter                0.18  0.03

As of December 31, 2010, the Company had 100,000,000 shares of common stock
authorized with 28,719,854, issued and outstanding.  The Company had 5,000,000
shares of preferred stock authorized with no shares issued and outstanding.

                                     Page 7
<PAGE>
PENNY STOCK REGULATIONS

Our common stock is quoted in United States markets on the OTC BB under the
symbol "HSTC.OB." The sale price of our common stock has been reported as low as
$.03 per share. As such, the Company's common stock may be subject to provisions
of Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), commonly referred to as the "penny stock rule."

Section 15(g) sets forth certain requirements for transactions in penny stocks,
and Rule 15g-9(d) incorporates the definition of "penny stock" that is found in
Rule 3a51-1 of the Exchange Act. The SEC generally defines "penny stock" to be
any equity security that has a market price less than $5.00 per share, subject
to certain exceptions. As long as the Company's common stock is deemed to be a
penny stock, trading in the shares will be subject to additional sales practice
requirements on broker-dealers who sell penny stocks to persons other than
established customers and accredited investors.

DIVIDENDS

The Company has not issued any dividends on the common stock to date, and does
not intend to issue any dividends on the common stock in the near future. We
currently intend to use all profits to further the growth and development of the
Company.

NUMBER OF SHARES OUTSTANDING

As of December 31, 2010, the Company had 100,000,000 shares of common stock
authorized with 28,719,854 issued and outstanding and 9,951,329 freely tradable
shares in the public float. These shares were held by approximately 590
shareholders of record. The Company had 5,000,000 shares of preferred stock
authorized with 1,000,000 shares issued and none outstanding.

RECENT SALES OF UNREGISTERED SECURITIES

The following represent all sales of unregistered securities during fiscal 2009
and the subsequent interim period up to the date hereof:

On October 28, 2008, the company received $250,000 from an investor for working
capital. This transaction was initially reported as a deposit from shareholder.
On June 9, 2009 the Company issued 200,000 shares at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On February 20, 2009, the company received $75,000 from an investor for working
capital. This investor was issued 60,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On March 16, 2009, the company received $25,000 from an investor for working
capital. This investor was issued 20,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On June 9, 2009, the company received $50,000 from an investor for working
capital. This investor was issued 40,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with

                                     Page 8
<PAGE>
Section 4(2) of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

On June 9, 2009, the company received $26,250 from an investor for working
capital. This investor was issued 21,000 shares, at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On June 10, 2009 the company issued 5,000 shares of common stock in exchange for
services rendered to the company. The shares were valued at $1.27 per share
which was the trading price of the shares on the date the shares were issued.

On July 15, 2009 the company issued 2,000 shares of common stock in exchange for
services rendered to the company. The shares were valued at $.82 per share which
was the trading price of the shares on the date the shares were issued.

On January 20, 2010 the company issued 1,714,286 shares of common stock to Ron
Howell as payment for consulting services performed during 2009.  The shares
were valued at $.07 per share.  This issuance was completed in accordance with
Section 4(2) of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

On January 20, 2010 the company issued 1,471,429 shares of common stock to Eric
Clemons as payment for consulting services performed during 2009.  The shares
were valued at $.07 per share.  This issuance was completed in accordance with
Section 4(2) of the Securities Act in an offering without any public offering or
distribution. These shares are restricted securities and include an appropriate
restrictive legend.

On April 23, 2010 the Company issued 150,000 shares of common stock in exchange
for services rendered to the Company.  The shares were valued at $.50 per share
which was the trading price of the shares on the date the shares were issued.

On May 20, 2010 the Company issued 150,000 shares of common stock in exchange
for services rendered to the Company.  The shares were valued at $.22 per share
which was the trading price of the shares on the date the shares were issued.

On February 2, 2011 the Company issued 1,000,000 shares of common stock to
Ronald Howell as payment for consulting services performed during 2010.  The
shares were valued at $.04 per share.  This issuance was completed in accordance
with Section 4(2) of the Securities Act in an offering without any public
offering or distribution.  These shares are restricted securities and include an
appropriate restrictive legend.

On February 2, 2011 the Company issued 7,000,000 shares of common stock in
exchange for debt owed during 2010.  The shares were valued at $.04 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution.  These shares
are restricted securities and include an appropriate restrictive legend.

PURCHASES OF EQUITY SECURITIES

None.

                                     Page 9
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA

Not required by smaller reporting companies.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATION

FORWARD-LOOKING STATEMENTS

Statements about our future expectations are "forward-looking statements" within
the meaning of applicable Federal Securities Laws, and are not guarantees of
future performance. When used herein, the words "may," "will," "should,"
"anticipate," "believe," "appear," "intend," "plan," "expect," "estimate,"
"approximate," and similar expressions are intended to identify such
forward-looking statements. These statements involve risks and uncertainties
inherent in our business, including those set forth in Item 1A under the caption
"Risk Factors," in this Annual Report on Form 10-K for the year ended December
31, 2010, and other filings with the SEC, and are subject to change at any time.
Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement.

OVERVIEW

HST Global, Inc. is an Integrated Health and Wellness Biotechnology company that
is developing and /or acquiring a network of Wellness Centers worldwide that are
primarily focused on the homeopathic and alternative treatment of late stage
cancer. In addition, the company intends to acquire innovative products for the
treatment of individual health challenges.  In this regard, the company
primarily focuses on homeopathic and alternative product candidates that are
undergoing or have already completed significant clinical testing.

The company has identified the growing acceptance of alternative treatments
worldwide which has placed us in a perfect position to open our own brand of
Treatment Centers. This strategy will enable the company to address the
challenges individuals face in the treatment challenging and in some cases life
threatening diseases.

PLAN OF OPERATION

General and administrative expenses consist primarily of salaries and related
personnel costs, professional fees, business insurance, rent, general legal
activities, and other corporate expenses.

We have never been profitable and do not anticipate having net income unless and
until we develop and/or acquire our wellness centers and/or develop new channels
of distribution.  With respect to our current activities, this is not likely to
occur until we obtain significant additional funding. We cannot provide any
assurance that we will be able to achieve profitability on a sustained basis, if
at all, obtain the required funding, obtain, or complete additional corporate
partnering or acquisition transactions.

Accordingly, we will need to raise additional funds or pursue strategic
transactions or other strategic alternatives. To date, we have financed our
operations primarily through private sales of our equity securities, and we
expect to continue obtaining required capital in a similar manner.

RESULTS OF OPERATIONS

Revenues, cost of sales and operating expenses
----------------------------------------------

                                    Page 10
<PAGE>
The Company had revenues of $0 for the year ended December 2010 as compared to
$0 for the year ended December 2009. The costs of sales for the same period were
$0 in 2010 as compared to $0 for 2009. The Company incurred expenses of $847,850
for the year ended December 2010. The expenses in 2010 were incurred to further
the company's Research and Development efforts and continue the company's
strategic plan of opening wellness clinics worldwide. Until the Company obtains
capital required to develop any properties or businesses and obtains the
revenues needed from its future operations to meet its obligations, the Company
will be dependent upon sources other than operating revenues to meet its
operating and capital needs. Operating revenues may never satisfy these needs.

Gain on discontinued operations
-------------------------------

No income or loss was recorded in the current quarter from discontinued
operations or from the disposal of a subsidiary.

LIQUIDITY AND CAPITAL RESOURCES

Our capital requirements arise principally due to our expenses in beginning our
operations and our plan to open up a Wellness Center in 2011. Our cash balance
as of December 31, 2010 was $560.

The Company does not currently have sufficient capital in its accounts, nor
sufficient firm commitments for capital to assure its ability to meet its
current obligations or to continue its planned operations. The Company is
continuing to pursue working capital and additional revenue through the seeking
of the capital it needs to carry on its planned operations. There is no
assurance that any of the planned activities will be successful.

OFF-BALANCE SHEET ARRANGEMENTS

None.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None.

ITEM  8.  FINANCIAL  STATEMENTS  AND  SUPPLEMENTARY  DATA

Description                                                                 Page
--------------------------------------------------------------------------  ----

Report of Independent Registered Public Accounting Firm                     F-12

Consolidated Balance Sheets                                                 F-13

Consolidated Statements of Operations                                       F-14

Consolidated Statements of Changes in Shareholders' Interest                F-15

Consolidated Statements of Cash Flows                                       F-17

Notes to Consolidated Financial Statements                                  F-18

                                    Page 11
<PAGE>
            REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and
Stockholders of HST Global, Inc. and Subsidiary
Hampton, Virginia


We have audited the accompanying consolidated balance sheets of HST Global, Inc.
and  subsidiary  as  of December 31, 2010 and 2009, and the related consolidated
statements  of operations, stockholders' equity (deficiency), and cash flows for
each  of  the  years in the two-year period ended December 31, 2010, and for the
period  from  the  date of inception on August 7, 2007 to December 31, 2010. HST
Global  Inc.'s  management  is  responsible  for these financial statements. Our
responsibility  is  to  express  an  opinion  on  these  consolidated  financial
statements  based  on  our  audits.

We  conducted  our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements  are  free  of  material misstatement. The company is not required to
have,  nor  were  we  engaged  to perform, an audit of its internal control over
financial  reporting.  Our audit included consideration of internal control over
financial  reporting  as  a  basis  for  designing  audit  procedures  that  are
appropriate  in  the  circumstances,  but  not  for the purpose of expressing an
opinion  on  the  effectiveness of the company's internal control over financial
reporting.  Accordingly,  we  express  no  such  opinion. An audit also includes
examining,  on  a test basis, evidence supporting the amounts and disclosures in
the  financial  statements,  assessing  the  accounting  principles  used  and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  We  believe  that  our  audits  provide  a
reasonable  basis  for  our  opinion.

In  our  opinion,  the financial statements referred to above present fairly, in
all material respects, the financial position of HST Global, Inc. and subsidiary
as of December 31, 2010 and 2009, and the results of its operations and its cash
flows  for  each of the years in the two-year period ended December 31, 2010 and
for the period from the date of inception on August 7, 2007 to December 31, 2010
in conformity with accounting principles generally accepted in the United States
of  America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company does not have the
necessary working capital to service its debt and for its planned activity,
which raises substantial doubt about its ability to continue as a going concern.
Management's plans in regard to these matters are described in Note 10 to the
financial statements. These financial statements do not include any adjustments
that might result from the outcome of this uncertainty.

/S/ MADSEN & ASSOCIATES CPA'S, INC.
Madsen & Associates CPA's, Inc.
Salt Lake City, Utah
May 12, 2011

                                      F-12
<PAGE>
                                HST GLOBAL, INC.
                         (a Development Stage Company)
                          CONSOLIDATED BALANCE SHEETS

                                                     December 31,  December 31,
                                                         2010          2009
                                                     ------------  ------------

ASSETS
CURRENT ASSETS:
  Cash and cash equivalents                          $       560   $     5,358
  Property, plant and equipment, net of
    accumulated depreciation                                 488         1,461
                                                     ------------  ------------

TOTAL ASSETS                                         $     1,049   $     6,819
                                                     ============  ============

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable and accrued expenses              $    65,300   $   111,623
  Accounts payable and accrued expenses -
    related parties                                      614,996       445,142
  Shareholder Deposits                                   200,000       200,000
  Advances from Shareholder                              569,741       246,556
  Notes payable - related parties                        396,000       331,636
                                                     ------------  ------------

Total Current Liabilities                            $ 1,846,037   $ 1,334,957

STOCKHOLDERS' EQUITY (DEFICIENCY):
  Preferred stock; 5,000,000 shares authorized;
    $.001 par value; 1,000,000 shares issued and
    none outstanding
  Capital stock, $.001 par value; 100,000,000
    shares authorized; 28,719,854 shares
    issued and outstanding at December 31, 2010;
    25,234,139 shares issued and outstanding
    at December 31, 2009                                  28,720        25,235
  Additional paid-in capital                           1,951,952     1,624,437
  Deficit accumulated during the development stage    (3,825,660)   (2,977,810)
                                                     ------------  ------------

Total Stockholders' Equity (Deficiency)              $(1,844,988)  $(1,328,138)
                                                     ------------  ------------

TOTAL LIABILITIES AND STOCKHOLDERS'EQUITY/(DEFICIT)  $     1,049   $     6,819
                                                     ============  ============

                        Please see the Accompanying Note

                                      F-13
<PAGE>
<TABLE>
<CAPTION>


                                            HST GLOBAL, INC.
                                      (a Development Stage Company)
                                  CONSOLIDATED STATEMENT OF OPERATIONS
                   For the years ended December 31, 2010 and 2009, and for the period
                    from the date of inception (august 6, 2007) to December 31, 2010

<S>                                    <C>                  <C>                  <C>
                                                                                 From Date of Inception
                                            Year Ended           Year Ended        (August 6, 2007) to
                                        December 31, 2010    December 31, 2009      December 31, 2010
                                       -------------------  -------------------  ------------------------

REVENUES                               $                -   $                -   $                     -

OPERATING EXPENSES:
Salaries                                                -               73,385                   176,031
Consulting                                        369,052              757,621                 1,962,000
General and administrative expenses               382,928              485,104                 1,506,129
                                       -------------------  -------------------  ------------------------

TOTAL OPERATING EXPENSES                          751,980            1,316,110                 3,644,160
                                       -------------------  -------------------  ------------------------

NET (LOSS) FROM OPERATIONS                       (751,980)          (1,316,110)               (3,644,160)

OTHER EXPENSES
Interest expense                                   95,870               46,502                   142,372

TOTAL OTHER EXPENSES                               95,870               46,502                   142,372
                                       -------------------  -------------------  ------------------------

NET (LOSS)                             $         (847,850)  $       (1,362,612)  $             3,786,532)
                                       ===================  ===================  ========================

NET INCOME (LOSS) PER SHARE:
BASIC AND DILUTED - COMMON             $            (0.03)  $            (0.05)
                                       ===================  ===================

WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED - COMMON                     28,632,354           25,113,894
                                       ===================  ===================
<FN>
                                    Please see the Accompanying Notes
</TABLE>
                                      F-14
<PAGE>
<TABLE>
<CAPTION>

                                                        HST GLOBAL, INC.
                                                  (a Development Stage Company)
                               CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
<S>                                  <C>      <C>        <C>         <C>       <C>          <C>           <C>        <C>
                                                                                                           Accum-
                                                                                                           ulated
                                                                                                            Other        Net
                                      Preferred Stock        Common Stock      Additional                  Compre-   Stockholders'
                                     ------------------  --------------------    Paid-In    Accumulated    hensive      Equity
                                     Shares    Amount     Shares      Amount     Capital      (Deficit)     (Loss)   (Deficiency)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------

Balance October 2, 2007 (inception)        0  $       -           0  $      -  $         -  $         -   $       -  $         -
Issuance of common stock
   for cash - October 2, 2007                                 1,500     1,500                                              1,500
  Net (Loss)                                                                                    (62,737)                 (62,737)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------
Balance - December 31, 2007                                   1,500     1,500                   (62,737)                 (61,237)

Recapitalization - reverse
  acquisition                                            24,030,353    22,533                   (39,128)                 (16,595)
Issuance of common stock for cash
  at $1.25 per share, August 2008                           839,200       839    1,048,161                             1,049,000
Issuance of common stock for
  services valued at $9.50 per
  share, August 2008                                         15,000        15      142,485                               142,500
  Net (loss) for period                                                                      (1,513,333)              (1,513,333)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------
Balances - December 31, 2008               -          -  24,886,053    26,387    1,190,646   (1,677,935)          -     (460,902)

Issuance of common stock for
  cash at $1.25 per share                                   141,086       317      175,933                               176,250
Issurance of common stock for
  stockholder
deposits at $1.25 per share                                 200,000        25      249,975                               250,000
Inssuance of common stock for
  services at $1.25 per share                                 5,000         5        6,245                                 6,250
Inssuance of common stock for
  services at $.82 per share                                  2,000         2        1,638                                 1,640
  Net (loss) for period                                                                      (1,362,612)              (1,362,612)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------
Balance-December 31, 2009                  0  $       -  25,234,139  $ 27,590  $ 2,815,083  $(2,977,810)  $       -  $(1,328,138)
                                     =======  =========  ==========  ========  ===========  ============  =========  ============

</TABLE>

                                      F-15
<PAGE>
<TABLE>
<CAPTION>
                                                        HST GLOBAL, INC.
                                                  (a Development Stage Company)
                          CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Cont'd)
<S>                                  <C>      <C>        <C>         <C>       <C>          <C>           <C>        <C>
                                                                                                           Accum-
                                                                                                           ulated
                                                                                                            Other        Net
                                      Preferred Stock        Common Stock      Additional                  Compre-   Stockholders'
                                     ------------------  --------------------    Paid-In    Accumulated    hensive      Equity
                                     Shares    Amount     Shares      Amount     Capital      (Deficit)     (Loss)   (Deficiency)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------

Insurrance of common stock for                            3,185,715  $  3,184  $   219,816                           $   223,000
  payment of accrued expenses
   at $.07 per share-1/10

Insurrance of common stock for
  payment of accrued expenses
  at $.50 per share-4/10                                    150,000  $    150  $    74,850                                75,000

Insurrance of common stock for
  payment of accrued expenses
  at $.22 per share-5/10                                    150,000  $    150  $    32,849                           $    33,000

Net (loss) for period                                                                       $  (847,850)             $  (847,850)
                                     -------  ---------  ----------  --------  -----------  ------------  ---------  ------------
Balance - December 31, 2010                              28,719,854  $ 28,720  $ 1,951,952  $(3,825,660)             $(1,844,988)

<FN>
                                                Please see the Accompanying Notes

</TABLE>
                                      F-16
<PAGE>
<TABLE>
<CAPTION>
                                               HST GLOBAL, INC.
                                         (a Development Stage Company)
                                     CONSOLIDATED STATEMENT OF CASH FLOWS
                      For the years ended December 31, 2010 and 2009, and for the period
                       from the date of inception (august 6, 2007) to December 31, 2010
<S>                                                      <C>           <C>                  <C>
                                                                                           From Date of Inception
                                                          Year Ended       December 31,     (August 6, 2007) to
                                                             2010              2009          December 31, 2010
                                                         ------------  -------------------  -------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)                                        $  (847,850)  $       (1,362,612)  $       (3,780,047)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization                                    972                  972                2,428
Common stock issued for services                                                    7,890              150,390
Changes in operating-assets and liabilities,
net of acquisitions:
Note payable - related parties                                64,364                                   196,000
Accrued payable and accrued expenses - related parties       500,854              425,914              939,521
Accounts payable and accrued expenses                        (46,323)             111,623               65,300
                                                         ------------  -------------------  -------------------
Net Cash used in Operating Activities                    $  (327,983)  $         (816,213)  $       (2,426,408)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment                                              -                    -               (2,917)
                                                         ------------  -------------------  -------------------
Net Cash used in Investing Activities                              -                    -               (2,917)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock                                                176,250            1,226,750
Deposits from shareholder                                                         200,000              450,000
Proceeds from notes payable - related parties                                     200,000              200,000
Advances from shareholder                                    323,185              244,546              569,731
Effect of merger adjustment                                        -                    -              (16,596)
                                                         ------------  -------------------  -------------------
Net cash provided by financing activities                    323,185              820,796            2,429,885

Net Increase (decrease) in cash                               (4,798)               4,583                  560
CASH AT BEGINNING OF PERIOD                                    5,358                  775                    -
                                                         ------------  -------------------  -------------------

CASH AT END OF PERIOD                                    $       560   $            5,358   $              560
                                                         ============  ===================  ===================

Cash paid for interest                                   $         -   $                -
                                                         ============  ===================
Cash paid for taxes                                      $         -   $                -
                                                         ============  ===================

NON-CASH FINANCING ACTIVITIES:
Common stock issued for services                         $         -   $            7,890   $          150,390
Common stock issued for payment of accrued expenses      $   331,000   $                -   $          331,000
Common stock issued for deposits                         $         -   $          250,000   $          250,000
<FN>
                                       Please see the Accompanying Notes
</TABLE>
                                      F-17
<PAGE>
                                HST GLOBAL, INC.
                                 AND SUBSIDIARY

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES

The Company was incorporated on April 11, 1984 under the laws of the State of
Delaware under the name of NT Holding Corporation. The Company has made several
acquisitions and disposals of various business entities and activities. On May
9, 2008, the Company entered into a Merger and share exchange agreement with
Health Source Technologies, Inc. This business acquisition has been accounted
for as a reverse merger or recapitalization of Health Source Technologies, Inc.
At the time of the merger NT Holding Corporation had disposed of its assets and
liabilities and had minimal operations and was considered a development stage
company. Immediately after the acquisition the Company changed its name to HST
Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of
the State of Nevada on August 6, 2007. The Company is currently headquartered in
Hampton, Virginia.

HST Global, Inc. is an integrated Health and Wellness Biotechnology company that
is developing and/or acquiring a network of Wellness Centers worldwide with the
primary focus on homeopathic and alternative treatments of late stage cancer and
other life threatening diseases.  In addition, the Company intends to acquire
innovative products for the treatment of life threatening diseases. The Company
primarily focuses on homeopathic and alternative product candidates that are
undergoing or have already completed significant clinical testing for the
treatment of late stage cancer and/or life threatening diseases.


NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS

The company considers all highly liquid instruments purchased with maturity of
three months or less to be cash equivalents.

REVENUE RECOGNITION

The company considers revenue to be recognized at the time the service is
performed.

USE OF ESTIMATES

The preparation of the Company's financial statements required management to
make estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from these
estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company's short-term financial instruments consist of cash and cash
equivalents and accounts payable. The carrying amounts of these financial
instruments approximate fair value because of their short-term maturities.
Financial instruments that potentially subject the Company to a concentration of
credit risk consist principally of cash. During the year the Company did not
maintain cash deposits at financial institutions in excess of the $250,000 limit
covered by the Federal Deposit Insurance Corporation. The Company does not hold
or issue financial instruments for trading purposes nor does it hold or issue
interest rate or leverage derivative financial instruments.

                                      F-18
<PAGE>
EARNINGS PER SHARE

Basic Earnings per Share ("EPS") is computed by dividing net income available to
common stockholders by the weighted average number of common stock shares
outstanding during the year. Diluted EPS is computed by dividing net income
available to common stockholders by the weighted-average number of common stock
shares outstanding during the year plus potential dilutive instruments such as
stock options and warrants. The effect of stock options on diluted EPS is
determined through the application of the treasury exercises are hypothetically
used to repurchase the Company's common stock at the average market price during
the period. Loss per share is unchanged on a diluted basis since the assumed
exercise of common stock equivalents would have an anti-dilutive effect.

INCOME TAXES

The Company uses the asset and liability method of accounting for income.  This
method requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of temporary differences between the carrying
amounts and the tax basis of certain assets and liabilities. Deferred income tax
assets and liabilities are computed annually for the difference between the
financial statement and tax bases of assets and liabilities that will result in
taxable or deductible amounts in the future, based on enacted tax laws and rates
applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established when necessary to reduce
deferred tax assets to the amount expected to be realized. Income tax expense is
the tax payable or refundable for the period, plus or minus the change during
the period in deferred tax assets and liabilities.

Deferred income taxes may arise from temporary differences resulting from income
and expense items reported for financial accounting and tax purposes in
different periods. Deferred taxes are classified as current or non-current,
depending on the classification of the assets and liabilities to which they
relate. Deferred taxes arising from temporary differences that are not related
to an asset or liability are classified as current or non-current depending on
the periods in which the temporary differences are expected to reverse. The
Company had no significant deferred tax items arise during any of the period
presented.

CONCENTRATION OF CREDIT RISK

The Company does not have any concentration of related financial credit risk.

RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not expect that the adoption of other recent accounting
pronouncements will have a material impact to its financial statements.

RECLASSIFICATIONS

The Company has made certain reclassifications in the balance sheet from the
prior year to make the financial statements consistent with the current year
balances

NOTE 3 - REVERSE MERGER, ACQUISITION AND BUSINESS DISPOSAL

On May 9, 2008, the Company entered into a merger and share exchange agreement
with NT Holding Corp. NT Holding Corp was incorporated on April 11, 1984 under
the laws of the State of Delaware. NT Holding Corp since its inception has been
involved in various business operations including mining and the development of
mineral properties. At the time of the merger and share exchange agreement, NT

                                      F-19
<PAGE>
Holding had disposed of its operation assets and previous operations and was
considered a development stage company.

This business acquisition has been accounted for as a reverse merger
(recapitalization) with Health Source Technologies, Inc. deemed to be the
accounting acquirer and NT Holding Corp deemed to be the legal acquirer.
Accordingly, the historical financial information statements presented herein
are those of Health Source Technologies, Inc. The accumulated deficit of the
accounting acquirer has been carried forward after the acquisition as well as
its assets and liabilities. Operations prior to the business combination are
those of the acquirer. In conjunction with this business combination, the Board
of Directors approved a 25 for 1 reverse split of the Company's common stock.
The stock splits have been applied retroactively in the financial statements as
if the split had occurred at the inception of the company.


NOTE 4 - STOCKHOLDERS EQUITY

The Company completed a business combination with Health Source Technologies
Inc. on May 9, 2008 (see Note 3). In conjunction with this acquisition the Board
of Directors approved a 25 for 1 reverse split of the Company's common stock.
Prior to the acquisition the Company had 30,039,203 shares of common stock
outstanding. The issuance of the 66,000,000 new shares of common stock to
facilitate the business combination gave the company a total of 96,039,203
shares outstanding immediately before the stock split. After the stock split
there were 4,041,568 shares outstanding. In addition, the post-acquisition
equity structure was to reflect a 95% ownership by the shareholders of Health
Source Technologies, Inc. In order to facilitate this structure, an additional
99,744,800 pre-split shares were issued and delivered to HST shareholders once
sufficient authorized capital was available. On December 31, 2008, 3,989,792
post split shares were issued. On December 31, 2008, 3,989,792 post split shares
were issued to Ron Howell, an officer and shareholder of the Company and Eric
Clemons, a shareholder of the Company to complete the terms of the acquisition
agreement. These shares have been retroactively reported in the financial
statements as being issued in conjunction with the acquisition that occurred on
May 5, 2008.

As part of the consideration for this business combination there were also
1,000,000 shares of preferred stock issued which where convertible into 16.2
(post split) shares of the company's common stock. These preferred shares were
converted into 16,200,000 shares of common stock.

The Company has received $1,049,000 from various persons and companies as
deposits that were being held by the company in the anticipation of fulfilling a
common stock subscription agreement. On August 20, 2008 the Company issued
839,200 shares of its common stock at a purchase price of $1.25 per share. Also,
on August 20, 2008 the company issued 15,000 shares of common stock in exchange
for legal services rendered to the company. The shares were valued at $9.50 per
share which was the trading price of the shares on the date the shares were
issued.

On October 28, 2008, the company received $250,000 from an investor for working
capital. This transaction was initially reported as a deposit from shareholder.
On June 9, 2009 the Company issued 200,000 shares at a price of $1.25 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution. These shares are
restricted securities and include an appropriate restrictive legend.

On February 20, 2009, the company received $75,000 from an investor for the
purchase of common stock. This investor was issued 60,000 shares, at a price of
$1.25 per share. This issuance was completed in accordance with Section 4(2) of
the Securities Act in an offering without any public offering or distribution.
These shares are restricted securities and include an appropriate restrictive
legend.

                                      F-20
<PAGE>
On March 16, 2009, the company received $25,000 from an investor for the
purchase of common stock. This investor was issued 20,000 shares, at a price of
$1.25 per share. This issuance was completed in accordance with Section 4(2) of
the Securities Act in an offering without any public offering or distribution.
These shares are restricted securities and include an appropriate restrictive
legend.

On June 9, 2009, the company received $50,000 from an investor for the purchase
of common stock. This investor was issued 40,000 shares, at a price of $1.25 per
share. This issuance was completed in accordance with Section 4(2) of the
Securities Act in an offering without any public offering or distribution. These
shares are restricted securities and include an appropriate restrictive legend.

On June 9, 2009, the company received $26,250 from an investor for the purchase
of common stock. This investor was issued 21,000 shares, at a price of $1.25 per
share. This issuance was completed in accordance with Section 4(2) of the
Securities Act in an offering without any public offering or distribution. These
shares are restricted securities and include an appropriate restrictive legend.

On June 10, 2009 the company issued 5,000 shares of common stock in exchange for
services rendered to the company. The shares were valued at $1.27 per share
which was the trading price of the shares on the date the shares were issued.

On July 15, 2009 the company issued 2,000 shares of common stock in exchange for
services rendered to the company. The shares were valued at $.82 per share which
was the trading price of the shares on the date the shares were issued.

On January 20, 2010 the Company issued 1,714,286 shares of common stock to Ron
Howell as payment for consulting services performed during 2009.  The shares
were valued at $.07 per share.  This issuance was completed in accordance with
Section 4(2) of the Securities Act in an offering without any public offering or
distribution.  These shares are restricted securities and include an appropriate
restrictive legend.

On January 20, 2010 the Company issued 1,471,429 shares of common stock to Eric
Clemons as payment for consulting services performed during 2009.  The shares
were valued at $.07 per share.  This issuance was completed in accordance with
Section 4(2) of the Securities Act in an offering without any public offering or
distribution.  These shares are restricted securities and include an appropriate
restrictive legend.

On April 23, 2010 the Company issued 150,000 shares of common stock in exchange
for services rendered to the Company.  The shares were valued at $.50 per share
which was the trading price of the Shares on the date the shares were issued.

On May 20, 2010 the Company issued 150,000 shares of common stock in exchange
for services rendered to the Company.  The shares were valued at $.22 per share
which was the trading price of the shares on the date the shares were issued.

On February 2, 2011 the Company issued 1,000,000 shares of common stock to
Ronald Howell as payment for consulting services performed during 2010.  The
shares were valued at $.04 per share.  This issuance was completed in accordance
with Section 4(2) of the Securities Act in an offering without any public
offering or distribution.  These shares are restricted securities and include an
appropriate restrictive legend.

                                      F-21
<PAGE>
On February 2, 2011 the Company issued 7,000,000 shares of common stock in
exchange for debt owed during 2010.  The shares were valued at $.04 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution.  These shares
are restricted securities and include an appropriate restrictive legend.


NOTE 5 - ACCOUNTS PAYABLE AND ACCURED EXPENSES - RELATED PARTIES

Accounts payable and accrued expenses consist of the following at December 31,
2010 and 2009.

                                  12/31/10   12/31/09
                                 ---------  ---------
       The Health Network, Inc.  $ 284,498  $  94,073
       Ronald Howell               163,770    155,030
       Eric Clemons                166,728    191,039
                                 ---------  ---------
       Total                     $ 614,996  $ 445,142
                                 =========  =========

Please see Notes 6 and 8 for further explanation of these liabilities.


NOTE 6 - SHAREHOLDER DEPOSITS

During July and August of 2009, the company received a total of $200,000 from an
investor as a deposit for the purchase of common stock. This transaction has
been reported as shareholder deposits on the company's financial statements.

NOTE 7 - NOTES PAYABLE - RELATED PARTIES

In connection with the reverse acquisition described in note 3 to the financial
statements, the Company agreed to pay the former shareholders of the target
company the sum of $100,000.  This note does carry an interest amount and is
repayable upon demand by the holder of the note. Although the note does not
carry a stated interest rate, there is a provision that the Company would owe an
additional $50,000 if the note was note paid by a certain date or upon demand by
the holder of the note.  The Company did not repay the note by the due date and
has accrued an additional $50,000 owed under the terms of the note. Management
of the Company disputes the amount owed under this note and is currently
assessing the legal issues surrounding this obligation.

On November 25, 2009, the Company entered into an agreement with a shareholder
of the Company.  Under terms of this agreement, the Company received $200,000
from this individual in exchange for the issuance of a promissory note in the
principal amount of $200,000 and 200,000 shares of the Company's common stock.
Under the terms of the promissory note, the Company is obligated to repay the
principal amount of the note together with $20,000 interest on or before March
15, 2010.

As of December 31, 2010, the Company had not issued the shares of common stock.
The Company has accrued interest in the amount of $46,000 owed under the terms
of this agreement.  The Company recorded interest in the amount of $26,000 which
represents the 200,000 shares of common stock valued at $.13 per share which was
the trading price of the Company's common stock on the date the agreement was
executed by the Company.  The Company has also accrued an additional $20,000 as
interest owed at December 31, 2010 based upon the terms of the promissory note.

                                      F-22
<PAGE>
This company has not repaid this note and there is no provision for additional
interest once the note is in default.  This note was guaranteed by a former
consultant of the Company.  The Company disputes the amount owed under this note
and is currently assessing the legal issues surrounding this obligation.


NOTE 8 - ADVANCES FROM SHAREHOLDER

Mr. Howell has advanced $399,200 to the Company to assist with working capital
needs.  These advances accrue interest at a rate of six percent (6%) per annum
of the unpaid balance.  At December 31, 2010, the Company owes Mr. Howell the
amount of $430,867 which includes accrued interest in the amount of $31,667.

Mr. Clemons has advanced $124,335 to the Company loans to assist with working
capital needs.  These advances accrue interest at a rate of six percent (6%) per
annum of the unpaid balance.  At December 31, 2010 the Company has recognized a
liability to Mr. Clemons in the amount of $138,874 which includes accrued
interest in the amount of $14,539.

The Company disputes the amount that is owed to Mr. Clemons and is currently
assessing the legal issues concerning this obligation.


NOTE 9 - RELATED PARTY TRANSACTIONS

EXECUTIVE OFFICES

The Company's executive offices are located at 150 Research Dr., Hampton VA.
These offices are leased by The Health Network, Inc. ("THN"), of which Ron
Howell is President. THN allows the Company to use the office space without a
formal sublease or rental agreement.

The Company currently accrues $15,000 per month as a general operating fee,
which covers use of the office space, use of certain equipment, and various
other services. The company paid a total $10,000 to The Health Network during
2010.  At December 31, 2010, the Company owes THN an amount of $284,499 for
amounts due under this agreement.

CONSULTING AGREEMENTS

The Company has entered into a consulting agreement with Mr. Howell, President
of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month
for consulting services thru December 31, 2010.  Mr. Howell received 1,714,286
shares of common stock valued at $120,000 as a partial payment for amounts owed
under this agreement in January of 2010 and $0 during 2009.  The consulting
agreement may be terminated at will by the Company. The Company intends to
continue to engage Mr. Howell as a consultant until his consulting services are
no longer required.  As of December 31, 2010, the Company owes Mr. Howell
$163,770 under the agreement.

The Company has entered into a consulting agreement with Eric Clemons, a
shareholder of the Company, whereby the Company agreed to pay Mr. Clemons
$10,000 per month for consulting services through December 2009. This employment
agreement carried the provision that it could be extended beyond this date upon
mutual agreement by both parties and that the agreement could be canceled by the
Company at any time after that date.  Mr. Clemons received 1,471,419 shares of
common stock valued at $103,000 as a partial payment for amounts owed under this
agreement in January of 2010.  The Company continued to accrue amounts owed
under this agreement through July of 2010.  The balance owed to Mr. Clemons at

                                      F-23
<PAGE>
December 31, 2010 is $166,729.  The Company disputes this amount and is
currently assessing legal issues surrounding this obligation.


NOTE 10 - FINANCIAL CONDITION AND GOING CONCERN

The Company's financial statements have been presented on the basis that it will
continue as a going concern, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business. The Company
incurred a net loss from continuing operations of $847,850 for the year ended
December 31, 2010 and has an accumulated deficit of $3,825,660 at December 31,
2010. These factors raise substantial doubt as to its ability to obtain debt
and/or equity financing and achieve profitable operations.

There are no assurances that HSTC will be able to either (1) achieve a level of
revenues adequate to generate sufficient cash flow from operations; or (2)
obtain additional financing through either private placement, public offerings
and/or bank financing necessary to support its working capital requirements. To
the extent that funds generated from operations and any private placements,
public offerings and/or bank financing are insufficient, the Company will have
to raise additional working capital. No assurance can be given that additional
financing will be available, or if available, will be on terms acceptable to
HSTC. If adequate working capital is not available HSTC may be required to
curtail its operations.


NOTE 11 - SUBSEQUENT EVENTS

On February 2, 2011 the Company issued 1,000,000 shares of common stock to
Ronald Howell as payment for consulting services performed during 2010.  The
shares were valued at $.04 per share.  This issuance was completed in accordance
with Section 4(2) of the Securities Act in an offering without any public
offering or distribution.  These shares are restricted securities and include an
appropriate restrictive legend.

On February 2, 2011 the Company issued 7,000,000 shares of common stock in
exchange for debt owed during 2010.  The shares were valued at $.04 per share.
This issuance was completed in accordance with Section 4(2) of the Securities
Act in an offering without any public offering or distribution.  These shares
are restricted securities and include an appropriate restrictive legend



                                      F-24
<PAGE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES

None.

ITEM 9A. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures

Our management, including our Principal Executive and Principal Financial
Officer, evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Securities Exchange Act Rules
13a-15(e) and 15d-15(e)) as of December 31, 2010. Our disclosure controls and
procedures are designed to ensure that information required to be disclosed by
the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a
et seq.) is recorded, processed, summarized, and reported, within the time
periods specified in the Commission's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by an issuer in the reports
that it files or submits under the Act is accumulated and communicated to the
issuer's management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow
timely decisions regarding required disclosure. Based on this evaluation, our
Chief Executive and Principal Financial Officer concluded that our disclosure
controls and procedures were not effective as of December 31, 2010.

(b) Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal
control over financial reporting as defined in Rules 13a-15(f) and 15d-a5(f)
under the Exchange Act. Our internal control over financial reporting is
designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in
accordance with U.S. GAAP. Our internal control over financial reporting
includes those policies and procedures that: (i) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of our assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial
statements in accordance with GAAP, and that our receipts and expenditures are
being made only in accordance with authorizations of our management and
directors; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use of disposition of our assets that
could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.

Under the supervision of our Chief Executive Officer and Chief Financial
Officer, our management assessed the effectiveness of our internal control over
financial reporting as of December 31, 2010. In making this assessment,
management used the criteria set forth in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, our management has concluded that our internal control
over financial reporting was ineffective as of December 31, 2010 and there are
material weaknesses in our internal control over financial reporting. A material
weakness is a deficiency, or a combination of control deficiencies, in internal
control over financial reporting such that there is a reasonable possibility
that a material

                                    Page 25
<PAGE>
misstatement of our annual or interim financial statements will not be prevented
or detected on a timely basis.

The material weaknesses relate to the limited number of persons responsible for
the recording and reporting of financial information, the lack of separation of
financial reporting duties, and the limited size of our management team in
general. We are in the process evaluating methods of improving our internal
control over financial reporting, including the possible addition of financial
reporting staff and the increased separation of financial reporting
responsibility, and intend to implement such steps as are necessary and possible
to correct these material weaknesses.

This annual report does not include an attestation report of our registered
public accounting firm regarding internal control over financial reporting.
Management's report was not subject to attestation by our registered public
accounting firm pursuant to temporary rules of the SEC that permit us to provide
only management's report in this Annual Report on Form 10-K. Our registered
public accounting firm will not be required to opine on internal controls until
fiscal 2010.

(c) Change in Internal Controls

There were no changes in our internal control over financial reporting during
the quarter ended December 31, 2010, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.

ITEM 9B. OTHER INFORMATION

None.


                                    PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

DIRECTOR AND EXECUTIVE OFFICER SUMMARY

The following table sets forth the names, ages, and principal offices and
positions of our current directors, executive officers, and persons we consider
to be significant employees. The Board of Directors elects our executive
officers annually. Our directors serve one-year terms or until their successors
are elected, qualified and accept their positions. The executive officers serve
terms of one year or until their death, resignation or removal by the Board of
Directors. There are no family relationships or understandings between any of
the directors and executive officers. In addition, there was no arrangement or
understanding between any executive officer and any other person pursuant to
which any person was selected as an executive officer.

     NAME OF DIRECTOR OR OFFICER  AGE  POSITION
     Ronald R. Howell              63  Chief Executive Officer,
                                       Chairman of the Board of Directors and
                                       Interim Chief Financial Officer

     Bradley C. Robinson           42  Director

                                    Page 26
<PAGE>
EXECUTIVE OFFICER AND DIRECTOR BIOS

RONALD R. HOWELL, CHIEF EXECUTIVE OFFICER, CHAIRMAN AND INTERIM CHIEF FINANCIAL
OFFICER: Mr. Howell has over 30 years of diversified leadership experience. He
has distinguished himself in various businesses and held executive positions in
various industries including real estate, distribution, national and
international sales, wholesale and retail marketing, financial service. Mr.
Howell serves as the CEO and President of The Health Network, Inc. and has
served in that capacity for over 5 years. The Health Network, Inc. is a direct
sales and marketing company in the nutraceutical industry.

Holding a Bachelor's Degree in Management from the University of Maryland and an
MBA from the Sellinger School of Business and Management at Loyola College, Mr.
Howell has also taught as an Adjunct Professor at Loyola College in Baltimore,
Maryland. Ron also served his country as a United States Marine.

BRADLEY C. ROBINSON, DIRECTOR: Mr. Robinson brings operational, business
development and venture financing experience to the company.  The majority of
this experience was developed during early stage structuring of ventures in the
areas of pharmaceuticals and medical devices.

Mr. Robinson is Executive Vice President, Business Development of Juneau
Biosciences, LLC.  Previous to his joining Juneau he was the CEO and co-founder
of Infusive Technologies, LLC, which resulted in an asset acquisition by Sagent
Pharmaceuticals, Inc. As part of the acquisition Mr. Robinson became President
of the medical device division of Sagent Pharmaceuticals. Sagent Pharmaceuticals
is a specialty injectable pharmaceutical products company.

Mr. Robinson studied accounting at the University of Utah and earned an MBA/MIM
from the Graduate School of International Management (Thunderbird).

LEGAL AND DISCIPLINARY HISTORY

No officer, director or control person of the Company has been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending
criminal proceeding (excluding traffic violations and other minor offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed,
suspended or vacated, by a court of competent jurisdiction that permanently or
temporarily enjoined, barred, suspended or otherwise limited such person's
involvement in any type of business, securities, commodities, or banking
activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil
action), the Securities and Exchange Commission, the Commodity Futures Trading
Commission, or a state securities regulator of a violation of federal or state
securities or commodities law, which finding or judgment has not been reversed,
suspended, or vacated; or

4. The entry of an order by a self-regulatory organization that permanently or
temporarily barred, suspended or otherwise limited such person's involvement in
any type of business or securities activities.

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act")
requires our directors and officers, and persons who own more than ten percent
of the Common Stock to file reports of ownership and changes in ownership with
the Securities and Exchange Commission ("SEC") and the American

                                    Page 27
<PAGE>
Stock Exchange. SEC regulations require reporting persons to furnish us with
copies of all Section 16(a) forms they file.

Based solely on our review of the copies of the Forms 3, 4 and 5 and amendments
thereto furnished to us by the persons required to make such filings during
fiscal 2009 and our own records, we believe that Mr. Howell, and Mr. Clemons
each failed to file timely a Form 3 to report initial beneficial ownership.

CORPORATE GOVERNANCE.

We have not adopted a code of ethics do date. We are in the process of
evaluating the standards of conduct necessary for the deterrence of malfeasance
and the promotion of ethical conduct and accountability, and will determine
whether a code of ethics is necessary based on our evaluation.

The Company does not have a standing Nominating Committee. There have been no
changes to the procedures whereby security holders may recommend nominees to the
registrant's board of directors.

The Company is not a "listed issuer" as defined by Rule 10A-3, and does not have
a standing Audit Committee. We do not have a financial expert serving on our
board of directors.

ITEM 11. EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS

OBJECTIVES AND PHILOSOPHY OF OUR EXECUTIVE COMPENSATION PROGRAM
---------------------------------------------------------------

We do not have a standing compensation committee. Our board of directors as a
whole makes the decisions as to employee benefit programs and officer and
employee compensation. The primary objectives of our executive compensation
programs are to:

-     attract, retain and motivate skilled and knowledgeable individuals;
-     ensure that compensation is aligned with our corporate strategies and
business objectives;
-     promote the achievement of key strategic and financial performance
measures by linking short-term and long-term cash and equity incentives to the
achievement of measurable corporate and individual performance goals; and
-     align executives' incentives with the creation of stockholder value.

To achieve these objectives, our board of directors evaluates our executive
compensation program with the objective of setting compensation at levels they
believe will allow us to attract and retain qualified executives. In addition, a
portion of each executive's overall compensation is tied to key strategic,
financial and operational goals set by our board of directors. We also generally
provide a portion of our executive compensation in the form of options that vest
over time, which we believe helps us retain our executives and align their
interests with those of our stockholders by allowing the executives to
participate in our longer term success as reflected in asset growth and stock
price appreciation.

NAMED EXECUTIVE OFFICERS
------------------------

The following table identifies our principal executive officer, our principal
financial officer and our most highly paid executive officers, who, for purposes
of this Compensation Disclosure and Analysis only, are referred to herein as the
"named executive officers."

     Name          Corporate Office
     ----------    -------------------------------
     Ron Howell    Chief Executive Officer and
                   Interim Chief Financial Officer

                                    Page 28
<PAGE>
COMPONENTS OF OUR EXECUTIVE COMPENSATION PROGRAM
------------------------------------------------

At this time, Named Executive Officers receives compensation for their services
to the Company. Compensation will be negotiated in the near future and may be
contingent on the availability of financing. The primary elements of our
executive compensation program will be base salaries and option grant incentive
awards, although the board of directors has the authority to award cash bonuses,
benefits and other forms of compensation as it sees fit.

The Company has entered into a consulting agreement with Mr. Howell whereby the
Company agreed to pay Mr. Howell $10,000 per month for consulting services thru
December 31, 2010. The consulting agreement may be terminated at will by the
Company. The Company intends to continue to engage Mr. Howell as a consultant
until his consulting services are no longer required.

We do not have any formal or informal policy or target for allocating
compensation between short-term and long-term compensation, between cash and
non-cash compensation or among the different forms of non-cash compensation.
Instead, we have determined subjectively on a case-by-case basis the appropriate
level and mix of the various compensation components. Similarly, we do not rely
on benchmarking against our competitors in making compensation related
decisions.

Base salaries
-------------

Base salaries will be used to recognize the experience, skills, knowledge and
responsibilities required of our named executive officers. Base salary, and
other components of compensation, may be evaluated by our board of directors for
adjustment based on an assessment of the individual's performance and
compensation trends in our industry.

Equity Awards
-------------

Our stock option award program will be the primary vehicle for offering
long-term incentives to our executives. To date, we have not issued any equity
awards. We intend our equity awards to executives to generally be made in the
form of warrants. We believe that equity grants in the form of warrants provide
our executives with a direct link to our long-term performance, create an
ownership culture, and align the interests of our executives and our
stockholders.

Cash bonuses
------------

Our board of directors has the discretion to award cash bonuses based on our
financial performance and individual objectives. The corporate financial
performance measures (revenues and profits) will be given the greatest weight in
this bonus analysis. We have not yet granted any cash bonuses to any named
executive officer nor have we yet developed any specific individual objectives
while we wait to attain revenue and profitability levels sufficient to undertake
any such bonuses.

Benefits and other compensation
-------------------------------

Our named executive officers are permitted to participate in such health care,
disability insurance, bonus and other employee benefits plans as may be in
effect with the Company from time to time to the extent the executive is
eligible under the terms of those plans. As of the date of this Registration
Statement, with exception to health care, we have not implemented any such
employee benefit plans.

                                    Page 29
<PAGE>
CURRENT COMPENSATION AGREEMENTS

As discussed below, we have not agreed to pay the Named Executive Officers an
annual salary. We will negotiate base salary in the near future. Base salary may
be increased from time to time with the approval of the board of directors. The
following table summarizes the agreed annual salary of each of the named
executive officers:

SUMMARY ANNUAL SALARY
---------------------

Name          Annual Salary
----------    --------------
Ron Howell    0(1)

(1)  Mr. Howell has agreed to defer receiving an annual salary. He has received
     $10,000 per month thru December 31, 2010 from the Company pursuant to a
     consulting agreement. See "Relationships and Related Transactions," below.

RON HOWELL, CHIEF EXECUTIVE OFFICER:

Mr. Howell currently does not receive compensation for his services as Chief
Executive Officer. He has agreed to defer compensation until the Company obtains
sufficient financing. The Board of Directors will determine what level of
compensation is appropriate to offer Mr. Howell in the near future.

GRANTS OF PLAN-BASED AWARDS TABLE FOR FISCAL YEAR 2008

The Company currently does not participate in any equity award plan. During
fiscal 2010, we did not grant any equity awards under any equity award plan.

OPTION EXERCISES FOR FISCAL 2009

During fiscal 2010, none of the named executive officers exercised options.

NONQUALIFIED DEFERRED COMPENSATION

To date, we currently offer no defined contribution or other plan that provides
for the deferral of compensation on a basis that is not tax-qualified to any of
our employees, including the named executive officers.

COMPENSATION OF DIRECTORS

We intend to use a combination of cash and equity-based compensation to attract
and retain candidates to serve on our board of directors. We intend to
compensate directors who are also our employees for their service on our board
of directors. Therefore, Mr. Howell will receive compensation for his service on
our board of directors, which compensation has not yet been determined.

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

We do not currently have a standing Compensation Committee. Our entire board of
directors participated in deliberations concerning executive officer
compensation.

COMPENSATION COMMITTEE REPORT

The board of directors has reviewed and discussed the Compensation Discussion
and Analysis required by Item 402(b) of Regulation S-K with management and,
based on such review and discussions, the board of directors has recommended
that this Compensation Discussion and Analysis be included in this Registration
Statement on Form 10.

                                    Page 30
<PAGE>
<TABLE>
<CAPTION>
SUMMARY COMPENSATION TABLE

The following table sets forth the total compensation paid to, or accrued by, the Named Executive Officers
and other employees earning over $100,000 per year during the fiscal year ended December 31, 2009. No
restricted stock awards, long-term incentive plan payout or other types of compensation, other than the
compensation identified in the chart below and its accompanying notes, were paid to these executive officers
during that fiscal year.
<S>         <C>   <C>            <C>            <C>            <C>           <C>           <C>      <C>
NAMED             ANNUAL         ANNUAL         OTHER          COMPENSATION  LONG TERM
EXECUTIVE         COMPENSATION   COMPENSATION   ANNUAL         RESTRICTED    COMPENSATION  LTIP
OFFICER     YEAR  SALARY($)      BONUS ($)      COMPENSATION   STOCK         OPTIONS       PAYOUTS  ALL OTHER
----------  ----  -------------  -------------  -------------  ------------  ------------  -------  ---------
Ron Howell  2009              0              0     120,000(1)             0             0        0          0
            2010              0              0     120,000(1)             0             0        0          0
Wes Tate,
Former CFO  2009              0              0             0              0             0        0          0
            2010              0              0             0              0             0        0          0
<FN>
1. Mr. Howell receives $10,000 per month from Health Source Technologies, Inc., the Company's operating
subsidiary, pursuant to a consulting agreement. Mr. Howell has been president of Health Source Technologies
since inception in 2007.
</TABLE>
<TABLE>
<CAPTION>
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END TABLE

The following table sets forth information regarding the outstanding warrants held by
our named officers as of December 31, 2009.
<S>         <C>              <C>                <C>               <C>        <C>
            OPTION AWARDS
            ---------------------------------------------------------------------------
                                                EQUITY INCENTIVE
            NUMBER OF        NUMBER OF          PLAN AWARDS:
            SECURITIES       SECURITIES         NUMBER OF
            UNDERLYING       UNDERLYING         SECURITIES        OPTION
            UNEXERCISED      UNEXERCISED        UNDERLYING        EXERCISE   OPTION
            OPTIONS          OPTIONS            UNEXERCISED       PRICE      EXPIRATION
NAME        (#) EXERCISABLE  (#) UNEXERCISABLE  UNEARNED OPTIONS  ($)        DATE
----------  ---------------  -----------------  ----------------  ---------  ----------
Ron Howell               -                  -                 -          -           -
</TABLE>
                                    Page 31
<PAGE>
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table shows the beneficial ownership of our common stock as of
March 1, 2010. The table shows the amount of shares owned by:

                          AMOUNT OF SHARES   PERCENT OF SHARES
IDENTITY OF               BENEFICIALLY       BENEFICIALLY
PERSON OR GROUP           OWNED              OWNED(1,2)            CLASS
------------------------  -----------------  ------------------  ------
Ronald R. Howell              19,041,982(2)              51.86%  Common
Chief Executive Officer,
Interim Chief Financial
Officer and Chairman
------------------------  -----------------  ------------------  ------
Eric Clemons                     2,741,229                7.47%  Common
------------------------  -----------------  ------------------  ------
Brad Robinson                            0                   0%  Common
Director
------------------------  -----------------  ------------------  ------
All Directors and               19,041,982               51.86%  Common
Officers as a Group
------------------------  -----------------  ------------------  ------

(1)  The  percentage  of  shares  owned  is  based  on  shares  of  common stock
outstanding  as  of  March  1,  2010. Where the beneficially owned shares of any
individual  or  group  in the following table includes any options, warrants, or
other  rights  to  purchase shares, the percentage of shares owned includes such
shares  as  if  the  right  to  purchase  had  been  duly  exercised.

(2)  Includes  11,371,982  held  personally,  and  7,670,000  held by The Health
Network,  Inc.,  of  which  he  is  President.

(3)  BENEFICIAL  OWNERSHIP  OF  SECURITIES:  Pursuant  to  Rule  13d-3 under the
Securities  Exchange  Act  of  1934,  involving  the determination of beneficial
owners of securities, a beneficial owner of securities is person who directly or
indirectly,  through  any  contract, arrangement, understanding, relationship or
otherwise  has,  or shares, voting power and/or investment power with respect to
the securities, and any person who has the right to acquire beneficial ownership
of  the  security  within sixty days through means including the exercise of any
option,  warrant  or  conversion  of  a  security.

ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

EXECUTIVE OFFICES

The Company's executive offices are located at 150 Research Dr., Hampton VA.
These offices are leased by The Health Network, Inc. ("THN"), of which Ron
Howell is President. THN allows the Company to use the office space without a
formal sublease or rental agreement.

The Company currently pays The Health Network, Inc. $15,000 per month as a
general operating fee, which covers use of the office space, use of certain
equipment, and various other services.

CONSULTING AGREEMENTS

The Company has entered into a consulting agreement with Mr. Howell whereby the
Company agreed to pay Mr. Howell $10,000 per month for consulting services thru
December 31, 2009. The consulting

                                    Page 32
<PAGE>
agreement may be terminated at will by the Company. The Company intends to
continue to engage Mr. Howell as a consultant until his consulting services are
no longer required.

DIRECTOR INDEPENDENCE

The Company is not listed on any national exchange, or quoted on any
inter-dealer quotation service, that imposes independence requirements on any
committee of the Company's directors, such as an audit, nominating or
compensation committee. The company's Board of Directors consists of Ron Howell,
who is not independent, and Mr. Robinson, who is independent.


ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following is a summary of the fees paid to Madsen & Associates, the
Company's independent public accounting firm, during the fiscal years ended
December 31, 2010 and 2009.

                            2010     2009
                         -------  -------
     Audit fees          $27,715  $30,500
     Audit-related fees        -        -
     Tax fees                  -        -
     All other fees            -        -
                         -------  -------
     TOTAL               $27,715  $30,500

AUDIT COMMITTEE PRE-APPROVAL OF SERVICES OF PRINCIPAL ACCOUNTANTS

We do not currently have an audit committee appointed by the Board of Directors
and the full Board of Directors did not vote on whether any non-audit services
impacted our auditor's independence. We currently do not have any policy for
approval of audit and permitted non-audit services by our independent auditor.
We plan to appoint an audit committee by our Board of Directors and adopt
procedures for approval of audit and non-audit services.


                                    PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

FINANCIAL STATEMENTS AND SCHEDULES.

The following consolidated financial statements of HST Global, Inc. are included
herein by reference to the pages listed in "Item 8. Financial Statements and
Supplementary Data":

     Report of Independent Registered Public Accounting Firm

     Consolidated Balance Sheets as of December 31, 2010 and 2009

     Consolidated Statements of Operations for the years ended December 31,
          2010, and 2009

     Consolidated Statements of Changes in Shareholders' Interest for the years
          ended December  31,  2010  and  2009

     Consolidated Statements of Cash Flows for the years ended December 31, 2010
          and 2009

     Notes to Consolidated Financial Statements

                                    Page 33
<PAGE>
     EXHIBITS

The following Exhibits are included herein:

No.   Description
----  ------------------------------------------------------------------------
31.1  Certification of the Principal Executive pursuant to Section 302 of the
      Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

31.2  Certification of the Principal Financial Officer pursuant to Section 302
      of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

32.1  Certification by the Principal Executive Officer of HST Global, Inc.
      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
      (18 U.S.C. 1350).

32.2  Certification by the Principal Financial Officer of HST Global, Inc.
      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
      (18 U.S.C. 1350).


                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                        HST GLOBAL, INC.
                                        (the registrant)


                                        By: \s\ Ron Howell
                                            --------------
                                        Ron Howell
                                        Chief Executive Officer


                                        Date: May 13, 2011











                                    Page 34